Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities
Biology of Blood and Marrow Transplantation, Volume 17, No. 6, Year 2011
Notification
URL copied to clipboard!
Description
Hematopoietic cell transplantation (HCT) offers potentially curative therapy for chronic myelomonocytic leukemia (CMML). We evaluated HCT outcomes in 85 patients with CMML, 1.0-69.1 (median 51.7) years of age, with follow-up extending to 19 years. CMML was considered de novo in 71 and secondary in 14 patients. Conditioning regimens were of various intensities. Thirty-eight patients had related (34 HLA identical), and 47 (39 HLA matched) unrelated donors. The source of stem cells was marrow in 32 and peripheral blood progenitor cells in 53 patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 72% and chronic GVHD (cGVHD) in 26% of patients. Relapse incidence was 27% at 10 years. Relapse correlated with increasing scores by the MD Anderson prognostic score (P = .01). The major causes of death were relapse and infections ±GVHD. Progression-free survival (PFS) was 38% at 10 years. Mortality was negatively correlated with pre-HCT hematocrit (P = .007), and increased with high-risk cytogenetics (P = .02), higher HCT Comorbidity Index (P = .0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease. © 2011 American Society for Blood and Marrow Transplantation.
Authors & Co-Authors
Eissa, Hesham
United States, Seattle
Fred Hutchinson Cancer Research Center
Egypt, Cairo
Nasser Institute for Research and Treatment
United States, Houston
Baylor College of Medicine
Gooley, Ted A.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Sorror, Mohamed L.
United States, Seattle
Fred Hutchinson Cancer Research Center
Nguyen, Franchesca
United States, Seattle
Fred Hutchinson Cancer Research Center
Scott, Bart L.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Doney, Kristine
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Loeb, Keith R.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Martin, Paul J.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Pagel, John M.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Radich, Jerald P.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Sandmaier, Brenda M.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Warren, Edus Houston
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Storb, Rainer
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Appelbaum, Frederick R.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Deeg, Hans Joachim J.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington School of Medicine
Statistics
Citations: 114
Authors: 15
Affiliations: 4
Identifiers
Doi:
10.1016/j.bbmt.2010.09.018
ISSN:
10838791
e-ISSN:
15236536
Research Areas
Cancer
Study Design
Cohort Study